Stock exchange and press releases of BBS will be published on these pages. Releases are published in Finnish and in English.
Contact information for the media: firstname.lastname@example.org from which you can also request additional media material.
BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document
BBS-Bioactive Bone Substitutes – Insider information: The company provides an update on the CE marking process related to the approval of the quality system – consultation with the Finnish Medicines Agency to begin on 21 November 2023
BBS-Bioactive Bone Substitutes – Inside information: The final report of the second audit received from the Notified Body, CE marking process may continue and CE marking approval continues to be expected during 2023
Older releases can be found from our news archive.